MA42341B2 - Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale - Google Patents

Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale

Info

Publication number
MA42341B2
MA42341B2 MA42341A MA42341A MA42341B2 MA 42341 B2 MA42341 B2 MA 42341B2 MA 42341 A MA42341 A MA 42341A MA 42341 A MA42341 A MA 42341A MA 42341 B2 MA42341 B2 MA 42341B2
Authority
MA
Morocco
Prior art keywords
preparation
protein kinase
kinase inhibitor
medical use
mesomer
Prior art date
Application number
MA42341A
Other languages
English (en)
Other versions
MA42341A1 (fr
Inventor
Lei Yin
Wenjian Liu
Heng Li
Dianxi Zhu
Original Assignee
Gan&Lee Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58796287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42341(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gan&Lee Pharmaceuticals filed Critical Gan&Lee Pharmaceuticals
Publication of MA42341A1 publication Critical patent/MA42341A1/fr
Publication of MA42341B2 publication Critical patent/MA42341B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne des composés tels que représentés dans la formule i ou un tautomère, un mésomère, un racémate, un énantiomère, un diastéréoisomère, un composé deutéré, un promédicament ou un mélange de ceux-ci, ou un sel ou un solvate pharmaceutiquement acceptable des composés tels que représentés dans la formule i ou un tautomère, un mésomère, un racémate, un énantiomère, un diastéréoisomère, un composé deutéré, un promédicament ou un mélange de ceux-ci, les r1 à r7 étant tels que définis
MA42341A 2015-11-30 2016-11-28 Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale MA42341B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510856641.1A CN106810536A (zh) 2015-11-30 2015-11-30 一种蛋白激酶抑制剂及其制备方法和医药用途
PCT/CN2016/107455 WO2017092635A1 (fr) 2015-11-30 2016-11-28 Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale

Publications (2)

Publication Number Publication Date
MA42341A1 MA42341A1 (fr) 2018-06-29
MA42341B2 true MA42341B2 (fr) 2021-05-31

Family

ID=58796287

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42341A MA42341B2 (fr) 2015-11-30 2016-11-28 Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale

Country Status (21)

Country Link
US (2) US11091476B2 (fr)
EP (1) EP3385262B1 (fr)
JP (2) JP6921101B2 (fr)
KR (1) KR20180083421A (fr)
CN (3) CN106810536A (fr)
AU (1) AU2016365366B2 (fr)
BR (1) BR112018010879A2 (fr)
CA (1) CA3002884A1 (fr)
CO (1) CO2018005854A2 (fr)
DK (1) DK3385262T3 (fr)
ES (1) ES2928169T3 (fr)
HU (1) HUE060152T2 (fr)
IL (1) IL259711B (fr)
MA (1) MA42341B2 (fr)
MX (1) MX387207B (fr)
PH (1) PH12018550049A1 (fr)
PT (1) PT3385262T (fr)
RU (1) RU2749437C2 (fr)
UA (1) UA124001C2 (fr)
WO (1) WO2017092635A1 (fr)
ZA (1) ZA201803531B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN111386272B (zh) 2017-10-27 2023-01-06 费森尤斯卡比肿瘤学有限公司 一种改进的瑞博西尼及其盐的制备方法
JP2021514359A (ja) 2018-02-15 2021-06-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． キナーゼ阻害剤としての複素環式化合物
WO2019170055A1 (fr) * 2018-03-05 2019-09-12 上海海和药物研究开发有限公司 Composés ayant une activité inhibitrice de kinase cdk4/6, composition pharmaceutique de ceux-ci et utilisation de ceux-ci
SG11202108004VA (en) * 2019-01-29 2021-08-30 Beta Pharma Inc 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
CN114364668B (zh) * 2019-06-21 2024-07-16 甘李药业股份有限公司 Cdk4/6抑制剂、及其盐和中间体的制备方法
AR119184A1 (es) * 2019-06-21 2021-12-01 Gan & Lee Pharmaceuticals Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas
CN116113628A (zh) * 2020-08-31 2023-05-12 甘李药业股份有限公司 一种含cdk4/6抑制剂的药物组合物
CN116583283A (zh) * 2020-09-21 2023-08-11 普莱鲁德疗法有限公司 Cdk抑制剂及其作为药物的用途
CA3205652A1 (fr) 2020-12-18 2022-06-23 Prelude Therapeutics Incorporated Inhibiteurs de cdk et leur utilisation en tant que produits pharmaceutiques
CN112390793B (zh) * 2021-01-19 2021-04-27 中国药科大学 Cdk6/dyrk2双靶点抑制剂及其制备方法和应用
CN117222636A (zh) * 2021-04-12 2023-12-12 甘李药业股份有限公司 作为cdk4/6抑制剂的氘代化合物
WO2022242563A1 (fr) * 2021-05-17 2022-11-24 甘李药业股份有限公司 Utilisation pharmaceutique d'un inhibiteur de cdk4/6
CN118119393A (zh) * 2021-09-14 2024-05-31 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
CN118339157A (zh) * 2021-12-24 2024-07-12 江苏恒瑞医药股份有限公司 氢化吲哚类化合物、其制备方法及其在医药上的应用
CN115093397B (zh) * 2022-06-07 2023-09-05 自贡市第三人民医院 一种用于治疗肿瘤的化合物、合成方法及应用
WO2024051717A1 (fr) * 2022-09-08 2024-03-14 上海深势唯思科技有限责任公司 Composé en tant qu'inhibiteur de plk1, son procédé de préparation et son utilisation
WO2024066986A1 (fr) * 2022-09-30 2024-04-04 楚浦创制（武汉）医药科技有限公司 Composé de 2-aminopyrimidine, utilisation et composition pharmaceutique de celui-ci

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
AU2001236698A1 (en) 2000-02-07 2001-08-14 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
CA2473026C (fr) * 2002-01-22 2011-05-03 Warner-Lambert Company Llc 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
US20070117818A1 (en) * 2004-02-04 2007-05-24 Masaichi Hasegawa Pyrimidinone compounds useful as kinase inhibitors
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
WO2008124085A2 (fr) * 2007-04-03 2008-10-16 Exelixis, Inc. Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2
WO2009017838A2 (fr) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinaisons d'inhibiteurs jak-2 et d'autres agents
MX2010008926A (es) 2008-02-15 2011-02-23 Rigel Pharmaceuticals Inc Compuestos de pirimidin-2-amina y su uso como inhibidores de jak cinasas.
CN102015689B (zh) 2008-05-16 2014-01-08 霍夫曼-拉罗奇有限公司 Jnk的抑制剂
JO2885B1 (en) * 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2013173506A2 (fr) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Procédé de traitement d'une dégradation musculaire
EP2909194A1 (fr) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibiteurs de cycline-dépendante kinase 7 (cdk7)
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
JP7368357B2 (ja) 2017-09-05 2023-10-24 ブラックソーン セラピューティクス インコーポレイテッド バソプレシン受容体アンタゴニストならびにそれに関連する生成物および方法
CN117222636A (zh) 2021-04-12 2023-12-12 甘李药业股份有限公司 作为cdk4/6抑制剂的氘代化合物

Also Published As

Publication number Publication date
ZA201803531B (en) 2021-10-27
HUE060152T2 (hu) 2023-02-28
EP3385262A1 (fr) 2018-10-10
US11091476B2 (en) 2021-08-17
AU2016365366B2 (en) 2021-03-04
MA42341A1 (fr) 2018-06-29
ES2928169T3 (es) 2022-11-15
MX2018006370A (es) 2018-09-24
RU2018122864A (ru) 2020-01-13
CN113956238A (zh) 2022-01-21
US20200165239A1 (en) 2020-05-28
PH12018550049A1 (en) 2018-10-29
EP3385262A4 (fr) 2019-06-19
CN106810536A (zh) 2017-06-09
KR20180083421A (ko) 2018-07-20
US11787801B2 (en) 2023-10-17
WO2017092635A1 (fr) 2017-06-08
PT3385262T (pt) 2022-10-18
DK3385262T3 (da) 2022-10-10
JP2019500413A (ja) 2019-01-10
IL259711B (en) 2022-08-01
CN113956238B (zh) 2023-07-14
EP3385262B1 (fr) 2022-07-13
AU2016365366A1 (en) 2018-05-17
CN108290864A (zh) 2018-07-17
CA3002884A1 (fr) 2017-06-08
IL259711A (en) 2018-07-31
RU2749437C2 (ru) 2021-06-10
US20210371418A1 (en) 2021-12-02
CN108290864B (zh) 2022-05-10
BR112018010879A2 (pt) 2018-11-21
JP6921101B2 (ja) 2021-08-18
UA124001C2 (uk) 2021-07-07
CO2018005854A2 (es) 2018-06-20
RU2018122864A3 (fr) 2020-03-17
MX387207B (es) 2025-03-18
JP2021138737A (ja) 2021-09-16

Similar Documents

Publication Publication Date Title
MA42341B2 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
MA52948B1 (fr) Composés
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA42339A1 (fr) Modulateurs du récepteur farnésoïde x
BR112018011475A2 (pt) compostos e métodos para modulação de quinase e indicação para a mesma
PH12016501440A1 (en) Novel heterocyclic compounds
MA56553B1 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btk
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
EA201591291A1 (ru) Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания
MA41607A (fr) Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
MA46101B1 (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
MA40302B1 (fr) Dérivés de carbazole
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
EP3502105A4 (fr) Forme polymorphe d'un composé inhibiteur de kinase, composition pharmaceutique le contenant, son procédé de préparation et son utilisation
MA39335A1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
MA39983B1 (fr) Dérivés de carboxamide
MX2021013576A (es) Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo.
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
FR3064634B1 (fr) Derives acryliques de 1 :4, 3 :6 dianhydrohexitol
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
MA50093B1 (fr) Composé pentacyclique
MA58104B1 (fr) Procédé et intermédiaire pour la préparation d'oxétane-2-ylméthanamine